An interventional study of Coronary artery sawtooth cutting balloon dilation catheter and Cutting balloon catheter in Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-13.
Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 22nd registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Biosensors Europe SA · Sites in Malaysia
Ages 18+
JW Medical Systems Ltd · Sites in China
Ages 18+
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18+
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 182 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 16 interventional studies, 1,121 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under JW Medical Systems Ltd, one of the names counted as Blue Sail Medical Co., Ltd.. Under that name alone:
JW Medical Systems Ltd is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the effectiveness and safety of the coronary serrated cutting balloon dilation catheter for the pre-dilation of coronary artery stenosis lesions.
This study is a prospective, multicenter, randomized controlled, non-inferiority designed clinical trial. It is planned to enroll a total of 182 eligible subjects from multiple research centers. The subjects will be randomly assigned to the experimental group (n = 91) and the control group (n = 91) in a 1:1 ratio. All subjects will undergo immediate coronary angiography after percutaneous transluminal coronary angioplasty (PTCA) to evaluate the success rate of the device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
① The age is between 18 and 80 years old (including the boundary values), and the subjects are male or non-pregnant female.
Have single or multiple coronary artery lesions and diagnosed ischemic heart disease (for example: stable angina pectoris, unstable angina pectoris, old myocardial infarction or asymptomatic myocardial ischemia).
There are coronary artery stenosis lesions confirmed by coronary angiography, which are suitable for percutaneous coronary intervention. The coronary artery stenosis is ≥ 70% (by visual estimation); or ≥ 50% (by visual estimation) and accompanied by evidence of ischemia, and the TIMI blood flow is ≥ Grade 1.
There are de novo or restenosis lesions in the coronary arteries of autologous or bypass graft vessels, and interventional treatment is required.
The visually estimated reference vessel diameter of the target lesion is 2.0mm - 4.0mm, and the lesion length is ≤ 20mm.
Be able to understand the purpose of the study, voluntarily participate and sign the form, and be able to and willing to accept the follow-up as specified in this trial.
Exclusion Criteria:
General Exclusion Criteria
Patients with (NYHA) Class IV heart failure.
Patients with to anti - and anticoagulant therapy and are unable to receive anticoagulant treatment.
Patients who have had any myocardial infarction within one week.
Patients with an allergic reaction to contrast agents. ⑤ Patients with severe renal failure, with a serum creatinine level > 2.0 mg/dl (177 μmol/L).
Patients who have undergone heart transplantation.
Patients who have had active peptic ulcer or active gastrointestinal bleeding within 1 month before surgery.
⑧ Patients who have had a stroke or within 3 months before surgery.
Tortuous lesions or lesions with an angulation of ≥ 45 degrees at the lesion site.
Lesions at the ostium with a distance of ≤ 2 mm from the left main coronary artery.
Target lesions that require treatment with coronary atherectomy or special balloons (such as scored balloons, spiked balloons, shock - wave lithotripsy systems, and cutting balloons of other brands).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Coronary artery sawtooth cutting balloon dilation catheter
Device: Cutting balloon catheter
Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a coronary artery sawtooth cutting balloon dilation catheter.
Ninety-one subjects who met the inclusion criteria were enrolled and randomly assigned to the treatment group using a cutting balloon catheter.
Device Procedural Success Rate
Time frame: one hour
Clinical treatment success rate
Time frame: one hour
acute lumen gain,ALG
Immediate lumen gain is defined as: ALG = the immediate minimum lumen diameter after balloon dilation - the minimum lumen diameter before the operation.
Time frame: one hour
The incidence of the composite endpoint of target lesion failure (TLF) within 30 days after surgery
Time frame: 30 days
The incidence of patient-related cardiovascular clinical composite endpoint (POCE) within 30 days after surgery
Time frame: 30 days
The incidence of major adverse cardiac events (MACE) within 30 days after surgery
Time frame: 30 days
Evaluation of Device Performance
CRF
Time frame: one hour
The incidence rate of medical device-related complications
Time frame: one hour
The incidence rate of device defects
Time frame: one hour
The incidence rate of adverse events and serious adverse events
Time frame: thirty days
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Dec 2025, 8 months later.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 8 months is below that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.